Incidence and survival for oropharynx and non-oropharynx head and neck cancers among veterans living with HIV

Angela L Mazul  
*Washington University School of Medicine in St. Louis*

Christine Hartman  
*M. E. DeBakey VA Medical Center, Houston*

Jennifer Kramer  
*Baylor College of Medicine*

Donna L White  
*Baylor College of Medicine*

Kathryn Royse  
*M. E. DeBakey VA Medical Center, Houston*

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

**Recommended Citation**  
Mazul, Angela L; Hartman, Christine; Kramer, Jennifer; White, Donna L; Royse, Kathryn; Raychaudhury, Suchismita; Sandulache, Vlad; Ahmed, Sarah T; Richardson, Peter; Sikora, Andrew G; and Chiao, Elizabeth, "Incidence and survival for oropharynx and non-oropharynx head and neck cancers among veterans living with HIV," *Cancer Medicine.*, . . (2020).  
https://digitalcommons.wustl.edu/open_access_pubs/10074
Authors
Angela L Mazul, Christine Hartman, Jennifer Kramer, Donna L White, Kathryn Royse, Suchismita Raychaudhury, Vlad Sandulache, Sarah T Ahmed, Peter Richardson, Andrew G Sikora, and Elizabeth Chiao
Incidence and survival for oropharynx and non-oropharynx head and neck cancers among veterans living with HIV

Angela L. Mazul1,2 | Christine Hartman3 | Jennifer Kramer3,4,5 | Donna L. White3,4 |
Kathryn Royse3 | Suchismita Raychaudhury4 | Vlad Sandulache6 | Sarah T. Ahmed3,4 |
Peter Richardson3 | Andrew G. Sikora6,7 | Elizabeth Chiao3,4,5

1Department of Otolaryngology/Head and Neck Surgery, Washington University School of Medicine, Saint Louis, MO, USA
2Division of Public Health Science, Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA
3VA Health Services Research Center of Innovations in Quality, Effectiveness, and Safety (IQuESt, Michael E. DeBakey VA Medical Center, Houston, TX, USA
4Department of Medicine, Baylor College of Medicine, Houston, TX, USA
5Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA
6Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA
7Otolaryngology Section, Operative Care Line Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

Abstract

Background: People living with HIV/AIDS (PLWH) have an excess risk for head and neck squamous cell carcinoma (HNSCC) compared to the general U.S. population, but little is known about HIV-specific risk factors associated with the incidence and outcomes HNSCC. We aim to identify clinical and HIV-specific risk factors associated with oropharyngeal and non-oropharyngeal HNSCC incidence and outcomes separately.

Methods: We constructed a retrospective cohort study of 45,052 PLWH aged 18 or above from the national Veteran Affairs (VA) Corporate Data from 1999 to 2015. We extracted demographic data and risk factor information, including history of alcohol abuse, smoking, CD4 count (cells/μl), and percent of follow-up time with undetectable HIV viral load as time-updated variables. We calculated the age-standardized incidence rates of oropharyngeal and non-oropharyngeal HNSCC and estimated adjusted hazard ratios (HR). We also examined overall survival using Kaplan–Meier curves and adjusted HR.

Results: The standardized incidence rate of oropharyngeal and non-oropharyngeal HNSCC in this veteran cohort of PLWH is 23.0 (95% confidence intervals (CIs): 17.1-28.9) and 55.4 (95% CI: 46.5-64.3) per 100,000 person-years, respectively. Nadir CD4 count ≤200 was associated with an increased risk of non-oropharyngeal HNSCC (HR: 1.78; 95% CI: 1.31-2.30 vs >200). Five-year overall survival of OPSCC (37.0%) was significantly lower than non-oropharyngeal HNSCC (49.1%).
1 | INTRODUCTION

In the United States, approximately, 1.1 million people are living with HIV. The total number of newly diagnosed HIV cases has remained stable between 2012 and 2016, with about 38,000 new cases a year. Since the introduction of effective combination antiretroviral therapy (ART), the life expectancy of people living with HIV/AIDS (PLWH) has been approaching that of the non-HIV population. Thus, there is a concern of an increasing rate of non-AIDS-defining cancers, including head and neck cancers, whose incidence sharply increases with aging in both HIV-infected and non-infected populations. PLWH have a higher incidence of both virus-related and tobacco/alcohol-related cancers due to a higher prevalence of HIV-induced inflammation, immunodeficiency, and tobacco use among PLWH compared with the non-HIV population. Indeed, as many as 20% of deaths among people living with HIV/AIDS is due to invasive non-AIDS-defining cancers.

Squamous cell carcinoma of the head and neck region (HNSCC) includes the oral cavity, oropharynx, hypopharynx, and larynx. Since HNSCC is strongly associated with tobacco use, the incidence for most of the sites has been decreasing. In stark contrast, the incidence of squamous cell carcinoma of the oropharynx (OPSCC) is rising at an epidemic rate due to its relationship with the human papillomavirus (HPV). OPSCC has now overtaken cervical cancer as the most common HPV-positive malignancy. Prior studies have shown that PLWH have an excess risk of HNSCC compared to the non-HIV population, which could be due to a higher prevalence of tobacco and alcohol use. However, the elevated risk of lung cancer—another smoking-related cancer—is not entirely explained by smoking, suggesting HIV-related immune suppression and chronic inflammation are also likely contributors. The drivers of increased HNSCC risk in PLWH patients are entirely unclear in the context of HPV-positive OPSCC. Since both HPV-negative and HPV-positive head and neck cancers have high levels of immune infiltrate, suggesting the immune system plays an essential role in HNSCC development and survival.

Given the heterogeneity in the risk of HNSCC in people living with HIV and the importance of the immune system, we aimed to identify risk factors associated with oropharyngeal and non-oropharyngeal HNSCC in a large retrospective cohort study of PLWH identified in the U.S. national Veterans Health Administration (VHA) system. We also examined factors associated with survival among veterans living with HIV with HNSCC.

2 | METHODS

2.1 Study population and design

We performed a retrospective cohort study using individual-level patient data from the national VA Corporate Data Warehouse (CDW) and the VA Central Cancer Registry (CCR) from 1999 to 2015. Detailed information about cohort construction and inclusion has been previously described. Briefly, the cohort of PLWH included patients aged 18 or above who fulfilled two out of the three following criteria: (1) patients with at least one positive HIV antibody test by Elisa or Western Blot; tested for HIV viral load (any +/- indeterminate); or tested for CD4+ count; (2) patients with at least one prescription in inpatient or outpatient pharmacy records for HIV antiretroviral therapy (ART); and (3) any inpatient or outpatient encounter with an International Classification of Diseases, Ninth Revision (ICD-9) (042 or V08) or ICD-10 code (B20 & Z21) for HIV. We used the earliest date of the HIV diagnostic criteria as the index date of follow-up unless it was before 10/01/1999 (inception date of CDW data), in which case we assigned 10/01/1999 as the HIV patient’s index date.

2.2 Variable specification

2.2.1 Outcomes

We are interested in two outcomes, first is HNSCC among the whole cohort and second survival among the HNSCC cohort (Figure 1). For the first incidence outcome (yellow box in Figure 1), we used a hierarchical approach to define the occurrence of OPSCC or non-oropharyngeal HNSCC in

Conclusions: PLWH who receive care in the VA had higher age-adjusted HNSCC incidence rates than reported in the general population, suggesting that HIV and immunosuppression play a role. Additional studies should be conducted to study the interaction between HPV and HIV.

KEYWORDS
head and neck cancer, HIV, incidence, survival
First, we identified all head and neck squamous cancer cases in the VA CCR based on primary site of OPSCC and non-oropharyngeal HNSCC defined as oral cavity, hypopharynx, and larynx cancer. We then identified patients with any ICD-9 or ICD-10 code for HNSCC (Table S1). We examined the discordance of cancer diagnosis between the VA CCR and ICD-9/ICD-10 with a manual review of the electronic medical record (EMR) to determine their true cancer status. This hierarchical approach ensured a high validity of all the captured cancer cases. We then excluded all prevalent cancer cases that were diagnosed any time before the HIV index date through to 90 days after the index date. For the second outcome of mortality (blue box in Figure 1), all-cause mortality was identified from the VA Vital Status file, which combines information from Medicare, VA, Social Security, and VA compensation and pension benefits to determine the date of death with a sensitivity of 98.3% and specificity of 99.8% when compared with the National Death Index. During follow-up, only one female developed non-oropharyngeal HNSCC, and none developed OPSCC. Thus, we excluded female patients from this study.

2.2.2 Covariates

We used a previously reported method to abstract and to classify covariates. Briefly, we extracted demographic data and risk factor information using ICD codes and pharmacy and laboratory data from the CDW, including age at index date, sex, race/ethnicity (White, Black, and other/unknown), history of alcohol abuse (yes, no), and smoking (ever or missing, never), and gastroesophageal reflux disease (GERD; ever, never). We defined baseline body mass index (BMI) by using the closest height and weight values in the 2 years before or after the index date. HIV-specific variables included were nadir CD4 count (cells/μL) and percent of follow-up time with undetectable HIV viral load, both as time-updated variables throughout the study period.

2.3 Statistical analysis

2.3.1 Incidence and risk factors for HNSCCs in veterans living with HIV

We compared baseline characteristics between patients with OPSCC, non-oropharyngeal HNSCC, and patients without an HNSCC diagnosis (i.e., controls) using a student’s t-test for continuous variables and chi-square tests for categorical variables. Therefore, follow-up time at risk was calculated from 90 days after the index date—the possible earliest start date of follow-up was 1/1/2000—to the development of HNSCC, death, or 12/31/2016, whichever was earlier. We calculated incidence rates age-standardized to the 2000 U.S. population for HNSCC in the PLWH per 100,000 person-years (PY) in oropharyngeal and non-oropharyngeal HNSCC separately. We then estimated adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for the risks of non-oropharyngeal
TABLE 1  Descriptive statistics of PLWH who received healthcare at VA from 1999 to 2015 by head and neck cancer diagnosis.

|                        | No cancer | Oropharyngeal | Non-oropharyngeal | p-value |
|------------------------|-----------|---------------|-------------------|---------|
|                        | n = 43,663 | n = 119 | n = 270          |         |
| Age at index date      |           |               |                   |         |
| <40                    | 9889 (22.7) | 14 (11.8) | 28 (10.4)         | <0.001  |
| 40-59                  | 28350 (64.9) | 91 (76.5) | 194 (71.9)        |         |
| 60 and above           | 5424 (12.4) | 14 (11.8) | 48 (17.8)         |         |
| Race                   |           |               |                   |         |
| Black                  | 22847 (52.3) | 68 (57.1) | 131 (48.5)        | 0.041   |
| Other/Unknown          | 4257 (9.8) | 6 (5.0) | 18 (6.7)          |         |
| White                  | 16559 (37.9) | 45 (37.8) | 121 (44.8)        |         |
| Smoking                |           |               |                   |         |
| Ever or unknown smoker | 35079 (80.3) | 104 (87.4) | 248 (91.9)        | <0.001  |
| Lifelong non-smoker    | 8584 (19.7) | 15 (12.6) | 22 (8.1)          |         |
| Alcohol abuse          |           |               |                   |         |
| No                     | 24605 (56.4) | 54 (45.4) | 157 (58.1)        | 0.046   |
| Yes                    | 19058 (43.6) | 65 (54.6) | 113 (41.9)        |         |
| Substance abuse        |           |               |                   |         |
| No                     | 24957 (57.2) | 55 (46.2) | 161 (59.6)        | 0.039   |
| Yes                    | 18706 (42.8) | 64 (53.8) | 109 (40.4)        |         |
| Baseline BMI           |           |               |                   |         |
| Missing                | 1543 (3.5) | 3 (2.5) | 7 (2.6)           | <0.001  |
| <25                    | 21063 (48.2) | 77 (64.7) | 157 (58.2)        |         |
| 25-29.9                | 14559 (33.3) | 26 (21.8) | 84 (31.1)         |         |
| >30                    | 6498 (14.9) | 13 (10.9) | 22 (8.1)          |         |
| GERD (ever)            |           |               |                   |         |
| No                     | 33277 (76.2) | 78 (65.6) | 166 (61.5)        | <0.001  |
| Yes                    | 10386 (23.8) | 41 (34.5) | 104 (38.5)        |         |
| HCV (ever)             |           |               |                   |         |
| No                     | 33882 (77.6) | 80 (67.2) | 198 (73.3)        | 0.006   |
| Yes                    | 9781 (22.4) | 39 (32.8) | 72 (26.7)         |         |
| Nadir CD4 (at cancer/censor) |         |           |                   |         |
| Missing                | 1409 (3.2) | 2 (1.7) | 10 (3.7)          | 0.061   |
| ≤200                   | 21159 (48.5) | 63 (52.9) | 152 (56.3)        |         |
| >200                   | 21095 (48.3) | 54 (45.4) | 108 (40.0)        |         |
| Viral load percentage of time undetectable (at cancer/censor) | | | | |
| Missing                | 1175 (2.7) | 1 (0.8) | 3 (1.1)           | 0.002   |
| <40%                   | 11081 (25.4) | 34 (28.6) | 98 (36.3)         |         |
| 40%-80%                | 11933 (27.3) | 35 (29.4) | 66 (24.4)         |         |
| >80%                   | 19474 (44.6) | 49 (41.2) | 103 (38.2)        |         |
| Year first HIV         |           |               |                   |         |
| Before 1996            | 8582 (19.7) | 41 (34.5) | 80 (29.6)         | <0.001  |
| 1996-2000              | 10161 (23.3) | 38 (31.9) | 93 (34.4)         |         |
| 2001-2005              | 9240 (21.2) | 20 (16.8) | 63 (23.3)         |         |
| 2006-2016              | 15680 (35.9) | 20 (16.8) | 34 (12.6)         |         |

Abbreviations: BMI, Body Mass Index; GERD, Gastroesophageal reflux disease; HCV, Hepatitis C virus; PLWH, People living with HIV.
HNSCC and OPSCC using Cox proportional hazards regression models from index date plus 90 days to cancer or censor. We used forward selection to include covariates that changed estimates more than 10% or deemed clinically relevant. We adjusted for age at index, race, smoking, baseline BMI, GERD, viral load percentage of time undetectable (time-dependent), nadir CD4 (time-dependent), and year first HIV diagnosis.

### 2.3.2 | Risk factors for mortality among People Living with HIV with HNSCC

We also examined survival using Kaplan–Meier curves for both oropharyngeal and non-oropharyngeal HNSCC as well as risk factors for mortality among PLWH with these cancers using Cox proportional hazards regression analysis the cancer date to death or censor. We examined the same potential confounder variables as examined in our Cox models for cancer incidence, as described above.

### 2.3.3 | HPV status exploratory analysis

To estimate the effect of HPV in OPSCC, we abstracted HPV status from medical records for all OPSCCs diagnosed after 2010 (HPV testing was not recommended 2010). Cases were classified as HPV-positive if the case was positive for either p16 immunohistochemistry or HPV in situ hybridization and as HPV-negative if one test was negative and the other was unknown or untested. We compared univariate demographics and survival between HPV-positive, HPV-negative, and unknown HPV status at OPSCC diagnosis using statistics described above. We did not perform Cox regression given limited power due to reduced sample size.

Analyses were performed using SAS version SAS Enterprise Guide Version 7.15 (SAS Institute, Cary, NC). Statistical significance was determined at α=0.05, and P-values for statistical significance were two-sided.

### 3 | RESULTS

#### 3.1 | Descriptive statistics

We included data from 44,052 veterans living with HIV/AIDS using VA healthcare. (Table 1). As expected, in our cohort, patients with OPSCC were younger than patients with non-oropharyngeal HNSCC (11.8% vs 17.8% older than 60 years at HIV index date, respectively) and controls (12.4% older than 60 years at HIV index date). OPSCC cases were more likely to be lifelong non-smokers compared with non-oropharyngeal HNSCC cases (12.6% vs 8.1% non-smoker, respectively) and controls (19.7%). OPSCC cases were more likely to have a history of alcohol abuse (54.6% in OPSCC vs 41.9% non-oropharyngeal HNSCC) and substance abuse (53.8% in OPSCC vs 40.4% non-oropharyngeal HNSCC) compared with both noncancer subjects and non-oropharyngeal HNSCC cases.

#### 3.2 | Incidence of OPSCC and non-oropharyngeal HNSCC in PLWH

Of the 44,052 PLWH in our nationwide VA cohort, there were 119 cases of incident OPSCC and 270 cases of non-oropharyngeal HNSCC. The age-standardized rate of OPSCC was 23.0 (95% CI: 17.1-28.9) per 100,000 PY. The age-standardized rate of non-oropharyngeal HNSCC was higher at 55.4 (95% CI: 46.5-64.3) per 100,000 PY.

In the adjusted Cox regression (Table 2), age greater than 60 years was associated with increased risk of both OPSCC (HR: 3.35; 95% CI: 1.56-7.18) and non-oropharyngeal HNSCC (HR: 5.80; 95% CI: 3.58-9.39) compared with age <40 years in PLWH. Ever smoking was only associated with risk of developing non-oropharyngeal HNSCC but not OPSCC (HR: 2.38; 95% CI: 1.53-3.71 vs HR: 1.28; 95% CI: 0.73-2.23, respectively). Nadir CD4 ≤200 was associated with an increased risk of non-oropharyngeal HNSCC (HR: 1.78; 95% CI: 1.31-2.30). GERD was also associated with the risk of non-oropharyngeal HNSCC (HR: 1.46; 95% CI: 1.14-1.87). Year of HIV diagnosis was significantly associated with decreased risk of both OPSCC (HR: 0.49; 95% CI: 0.28-0.85 for 2001-2005 vs prior to 1999) and non-oropharyngeal HNSCC (HR: 0.56; 95% CI: 0.36-0.88 for 2006-2016 vs prior to 1999).

#### 3.3 | Survival for HNSCC in PLWH patients

Overall survival (OS) for OPSCC (5-year OS: 37.0%; Figure 2) was significantly lower than that of non-oropharyngeal HNSCC (5-year OS: 49.1%; log-rank p-value=0.005). We further categorized non-oropharyngeal HNSCC into hypopharynx (n = 24), larynx (n = 120), nasopharynx (n = 11) and oral cavity (n = 115). Five-year OPSCC OS was lower than survival for both larynx (45.6%) and oral cavity cancer (65.4%; Figure S1A). These trends also continued when stratified by smoking, where smokers with OPSCC had a worse survival than smokers with non-oropharyngeal HNSCC (Figure S1B). The 5-year OS in stage III–IV was lower than stage I–II in both OPSCC (I–II: 40.4%, III–IV: 30.9%, Figure S1C) and non-oropharyngeal HNSCC (I–II: 66.2%, III–IV: 22.67%, Figure S1D).
TABLE 2 Mutually adjusted hazard ratios for the risk of oropharyngeal and non-oropharyngeal cancer in PLWH receiving healthcare at VA from 1999 to 2015.

|                          | Oropharyngeal HR (95% CI) | p-value | Non-oropharyngeal HR (95% CI) | p-value |
|--------------------------|---------------------------|---------|-------------------------------|---------|
| Age at index             |                           |         |                               |         |
| <40                      | 1.00                      |         | 1.00                          |         |
| 40-59                    | 2.17 (1.23, 3.84)         | 0.008   | 2.35 (1.57, 3.50)             | <0.001  |
| 60 and above             | 3.35 (1.56, 7.18)         | 0.002   | 5.80 (3.58, 9.39)             | <0.001  |
| Race                     |                           |         |                               |         |
| White                    | 1.000                     |         | 1.00                          |         |
| Black                    | 1.00 (0.68, 1.47)         | 0.993   | 0.77 (0.59, 0.99)             | 0.040   |
| Other/Unknown            | 0.65 (0.28, 1.54)         | 0.329   | 0.75 (0.46, 1.24)             | 0.264   |
| Smoking                  |                           |         |                               |         |
| Lifelong non-smoker      | 1.00                      |         | 1.00                          |         |
| Ever or unknown smoker   | 1.28 (0.73, 2.23)         | 0.386   | 2.38 (1.53, 3.71)             | <0.001  |
| Alcohol                  |                           |         |                               |         |
| No                       | 1.00                      |         | 1.00                          |         |
| Yes                      | 1.81 (1.23, 2.66)         | 0.003   | 1.16 (0.90, 1.51)             | 0.253   |
| Baseline BMI             |                           |         |                               |         |
| <25                      | 1.00                      |         | 1.00                          |         |
| 25-29.9                  | 0.48 (0.31, 0.76)         | 0.001   | 0.79 (0.60, 1.03)             | 0.081   |
| >30                      | 0.63 (0.35, 1.14)         | 0.130   | 0.56 (0.35, 0.87)             | 0.010   |
| Missing                  | 0.50 (0.16, 1.62)         | 0.250   | 0.52 (0.24, 1.12)             | 0.092   |
| GERD                     |                           |         |                               |         |
| No                       | --                       |         | 1.00                          |         |
| Yes                      | --                       |         | 1.46 (1.14, 1.87)             | 0.003   |
| Viral load percentage of time undetectable (time-dependent) |         |         |                               |         |
| <40%                     | 1.00                      |         | 1.00                          |         |
| 40%-80%                  | 1.19 (0.73, 1.95)         | 0.486   | 0.78 (0.56, 1.09)             | 0.144   |
| >80%                     | 1.29 (0.81, 2.07)         | 0.283   | 0.85 (0.63, 1.15)             | 0.288   |
| Missing                  | 1.50 (0.18, 12.28)        | 0.708   | 0.92 (0.27, 3.16)             | 0.895   |
| Nadir CD4 (time-dependent) |                         |         |                               |         |
| >200                     | 1.00                      |         | 1.00                          |         |
| ≤200                     | 1.39 (0.95, 2.02)         | 0.088   | 1.78 (1.31, 2.30)             | <0.001  |
| Missing                  | 0.38 (0.51, 2.28)         | 0.112   | 1.14 (0.56, 2.30)             | 0.721   |
| Year first HIV           |                           |         |                               |         |
| Before 1996              | 1.00                      |         | 1.00                          |         |
| 1996-2000                | 0.82 (0.52, 1.27)         | 0.366   | 1.02 (0.76, 1.38)             | 0.880   |
| 2001-2005                | 0.49 (0.28, 0.85)         | 0.011   | 0.83 (0.59, 1.17)             | 0.282   |
| 2006-2016                | 0.69 (0.38, 1.26)         | 0.223   | 0.56 (0.36, 0.88)             | 0.011   |

Abbreviations: BMI, Body Mass Index; GERD, Gastroesophageal reflux disease; PLWH, People living with HIV.

In multivariable Cox analysis for survival, ever smoking was significantly associated with increased risk of death, and BMI was associated with a decreased risk of death among both OPSCC and non-oropharyngeal HNSCC patients (Table 3). Although not significant, nadir CD4 count was also associated with OPSCC survival, where cases with nadir CD4 count less than or equal to 200 had 2.00 times the hazard of death (95% CI: 0.94-4.27) compared to those with nadir CD4 greater than 200.
3.4 HPV impact on OPSCC survival in PLWH

In our sensitivity analysis examining HPV in OPSCC, we found of the 62 cases diagnosed since 2010, 56.4% (n = 35) were tested for HPV. Of these, 88.6% (n = 31) were HPV-positive and 11.4% (n = 4) were HPV-negative. Older individuals, smokers, and those whose cancer was first diagnosed before 2013 were less likely to be tested (Table S2). In a Kaplan–Meier curve (Figure 3), HPV-negative and unknown cases had worse OS (5-year OS: 18.3%) than HPV-positive cases (5-year OS: 59.4%).

FIGURE 2 Kaplan–Meier curve for survival after between oropharyngeal and non-oropharyngeal cancer

4 DISCUSSION

In this large retrospective cohort study of veterans living with HIV using the nationwide VA healthcare system, we found that the age-standardized rate of non-oropharyngeal HNSCC is higher compared with age-standardized rates of OPSCC. The HIV-specific variable associated with non-oropharyngeal HNSCC was nadir CD4 count, which was associated with an increased risk of cancer. We are also the first study to demonstrate lower survival in OPSCC compared with laryngeal and oral cavity cancer in both PLWH and veterans. This trend is consistent when stratified by stage. Upon further inspection, we found evidence that, although HPV-positive OPSCC has better survival than non-HPV OPSCC, survival is still lower in PLWH than the non-HIV population.

The incidence of HNSCC is higher in PWLH compared with the general SEER population, which is paralleled in our study where we see a higher incidence of both OPSCC and non-oropharyngeal HNSCC. PLWH tend to have more risk factors for cancer, such as risky sexual behavior, smoking, and immunosuppression. The age-standardized incidence of OPSCC and non-oropharyngeal HNSCC in our study is higher than previously reported in North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) consortium (40 per 100,000 person-years and 10.7 per 100,000 person-years, respectively). The NA ACCORD consortium has pooled data from 17 prospective studies, including data from the VHA. However, our cohort was developed separately from the Veterans Aging Cohort (VACS) using a separate methodology. Additionally, male veterans who have a higher prevalence of cancer risk factors such as smoking and alcohol use thus represents a different target population from NA ACCORD.

Overall, we see results similar to those observed in the NA ACCORD consortium. Age appears to one of the most significant risk factors for HNSCC among PLWH, which is relevant given the aging PLWH population. We found no association between HIV-related factors and OPSCC, supporting previous research that immunosuppression is more relevant for non-HPV associated HNSCC than HPV-positive cancer. The increased but nonsignificant association of CD4 count may be due to the impact of CD4 early in HPV-positive cancer by affecting HPV persistence. On the contrary, for non-HPV-positive cancer, CD4 count would reflect reduced immune surveillance for malignant cells in the development of HNSCC. Alternatively, there is evidence that CD4 count decline could be due to undiagnosed cancer, rather than causing cancer. However, this has mainly been observed in lymphomas, and, in our study, the nadir CD4 count associated with cancer could be many years before the incident cancer diagnosis.

The relationship between GERD and non-oropharyngeal HNSCC is mixed with many earlier studies suggesting an association with hypopharynx or larynx cancer, but recent studies have not supported these findings. Our study is the first study of PLWH to examine GERD, in which we observed an association of GERD with non-oropharyngeal HNSCC. However, this association could be due to reverse causality, where the symptoms of laryngeal cancer mimic those of GERD. Thus, both are more likely diagnosed. Future studies may determine if this increased risk is simply due to detection bias.

This is the first large cohort study of HNSCC among PLWH that includes survival and stage. Survival in this cohort is lower than the SEER population for both OPSCC and non-oropharyngeal HNSCC. The lower survival compared to the non-veteran and non-HIV population could be due to the increased prevalence of smoking and medical conditions in the VA in addition to decreased immune response due to HIV. Low CD4 count is associated with increased risk of death in OPSCC, but non-oropharyngeal HNSCC. HPV-positive OPSCC tumors tend to have more immune infiltrated and have higher levels of T cells. We also found the...
Survival of OPSCC to be much lower than the survival of non-oropharyngeal HNSCC, even given the lower prevalence of suggesting there is an interaction between HIV and HPV in OPSCC. Coupled with increased risk among PLWH, immunity may play a more crucial role in HPV-positive cancers than in non-HPV-positive HNSCCs.

In a subset analysis, we found that among the cases tested for HPV, the majority are HPV-positive, which is similar to previous studies of HPV status in OPSCC in the VA. We also found that although HPV-positive OPSCC cases have better survival than HPV-negative OPSCC, they still have lower survival than the non-HIV population. Two-year survival for HPV-positive OPSCC for all stages has been reported to be as high as 90% in the non-HIV non-Veteran population. This difference in survival signifies that host immune likely plays an essential role in the increased survival of HPV-positive OPSCC. Smoking is also a likely driver of poor outcomes, particularly in the Veteran population with high rates of tobacco use. Smoking worsens prognosis in HPV-positive OPSCC, increasing the risk of death by 1% for every one pack-year of smoking. However, to date, few studies have considered the interaction between HIV and HPV in OPSCC, and one previous study of OPSCC among PLWH found no difference in survival by HPV status. This discordance justifies additional examination of the interaction between HPV and HIV in OPSCC specifically.

### TABLE 3 Mutually adjusted hazard ratios for risk of mortality among PLWH in the VA after oropharyngeal and non-oropharyngeal cancer diagnosis.

|                      | Oropharynx (N event = 80) | Non-oropharynx (N event = 147) |
|----------------------|---------------------------|-------------------------------|
|                      | N (%) HR (95% CI) p-value | N (%) HR (95% CI) p-value     |
| **Age at index date**|                           |                               |
| <40                  | 14 (11.8) 1.00             | 28 (10.4) 1.00                 |
| 40-59                | 91 (76.5) 1.04 (0.40, 2.69) 0.939 | 194 (71.9) 5.91 (1.85, 18.87) 0.003 |
| 60 and above         | 14 (1.8) 2.41 (0.75, 7.80) 0.141 | 48 (17.8) 9.04 (2.68, 30.45) <0.001 |
| **Smoking**          |                           |                               |
| Non-smoker           | 104 (87.4) 1.00            | 248 (91.9) 1.00                |
| Ever or unknown smoker | 15 (12.6) 2.96 (1.25, 6.99) 0.013 | 22 (8.1) 3.31 (1.35, 8.12) 0.009 |
| **Baseline BMI**     |                           |                               |
| <25                  | 77 (66.4) 1.00             | 157 (59.5) 1.00                |
| 25-29.9              | 26 (22.4) 0.80 (0.43, 1.49) 0.489 | 85 (32.2) 0.51 (0.34, 0.76) 0.001 |
| >30                  | 13 (11.2) 0.26 (0.09, 0.74) 0.012 | 22 (8.3) 0.86 (0.41, 1.81) 0.690 |
| **Viral load percentage of time undetectable (time-dependent*)**| | |
| <40%                 | 28 (23.7) 1.00             | 61 (22.8) 1.00                 |
| 40%-80%              | 39 (33.1) 1.31 (0.73, 2.34) 0.369 | 98 (36.7) 0.89 (0.58, 1.36) 0.588 |
| >80%                 | 51 (43.2) 0.71 (0.38, 1.32) 0.284 | 108 (40.4) 0.78 (0.51, 1.19) 0.244 |
| **Nadir CD4 (time-dependent*)**| | |
| >200                 | 106 (89.1) 1.00           | 195 (73.0) 1.00               |
| ≤200                 | 13 (10.9) 2.00 (0.94, 4.27) 0.072 | 72 (27.0) 1.11 (0.75, 1.64) 0.597 |
| **Stage**            |                           |                               |
| I-II                 | 22 (18.5) 1.00             | 119 (44.1) 1.00                |
| III-IV               | 86 (72.3) 1.52 (0.86, 2.71) 0.153 | 94 (34.8) 2.63 (1.79, 3.88) <0.001 |
| Unknown              | 11 (9.2) 0.70 (0.22, 2.26) 0.549 | 57 (21.1) 1.55 (0.97, 2.48) 0.069 |

Abbreviation: BMI, body mass index.

*N (%) is at cancer/censor index.

---

*Mutually adjusted hazard ratios for risk of mortality among PLWH in the VA after oropharyngeal and non-oropharyngeal cancer diagnosis.*
radiation therapy. ART-associated immune reconstitution fails to completely restore immune populations required for successful control of cancer after radiation therapy.

Our study has several limitations. First, it was a historical cohort and may be subject to unmeasured confounders such as sexual behavior and misclassification of covariates. However, we attempted to adjust for this through ICD-9 codes identifying individuals with a history of both alcohol and drug use. Although we were able to abstract HPV data on some of the OPSCC cases, we lacked information about the tumor HPV status of for most of the OPSCC cases, since only about half the cases after 2010 were tested for HPV. Finally, this study was limited to male veterans. Veterans are a select group that has lower socioeconomic status, more medical conditions, which would limit the generalizability to the other populations of PWLH.

Our study has multiple notable strengths. The VHA is the most extensive integrated healthcare system and provider of comprehensive HIV care in the United States. By taking advantage of the comprehensive fully automated nationwide VA clinical, laboratory, and administrative databases (CDW and CCR) along with manual electronic medical records abstractions, we constructed a large cohort of PLWH with extensive follow-up and individual-level data. Additionally, this is the largest study published to date evaluating HNSCC survival among PLWH.

In summary, HNSCC is more common among PLWH than in the general U.S. population. Certain HIV-specific variables such as CD4 count are associated with increased risk suggesting that HIV, and thus, the host immune system, in addition to increased prevalence of head and neck risk factors such as smoking and HPV, increases the risk of HNSCC. As the prevalence of both HIV rises in the United States due to better survival and the incidence of HPV-positive OPSCC increases, the interaction between the HPV and HIV becomes increasingly relevant, especially since HPV-positive OPSCCs among PLWH in our cohort do not have the generally favorable survival seen in the non-HIV population. This growing concern needs a dedicated effort and resources as well as additional studies to study the interaction between HPV, tobacco, and HIV in OPSCC.

AUTHOR CONTRIBUTIONS
EC, JK, and DLW conceived and designed this study. STA, KR, CH, and SR collected and curated the data. CH performed the data analysis. ALM, CH, KR, DLM, PR, and EC were involved with the interpretation. ALM drafted the article. ALM, CH, KR, DLW, KR, VS, STA, PR, AGS, and EC provided critical revision. All authors approved of the version to be published.

DATA AVAILABILITY STATEMENT
Data subject to third party restrictions. The data that support the findings of this study are available from Veteran Affairs. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors with the permission of Veteran Affairs.

ORCID
Angela L. Mazul https://orcid.org/0000-0002-1249-4613

REFERENCES
1. Centers for Disease Control and Prevention. Diagnoses of HIV Infection in the United States and Dependent Areas, 2017. HIV Surveillance Report, 2017. vol. 29.
2. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e81355.
3. Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4:e495-e504.
4. Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Current HIV/AIDS Rep. 2012;9:223-230.
5. Mourad M, Jetmore T, Jategaonkar AA, Moubayed S, Moshier E, Urken ML. Epidemiological trends of head and neck cancer in the United States: A SEER Population Study. J Oral Maxillofac Surg. 2017;75:2562-2572.
6. Retig EM, D’Souza G. Epidemiology of head and neck cancer. Surg Oncol Clin N Am. 2015;24:379-396.
7. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
8. Sigel K, Makinson A, Thaler J. Lung cancer in persons with HIV. Current Opinion in HIV and AIDS. 2017;12:31-38.
9. Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33:3293-3304.
10. Kramer JR, Hartman C, White DL, et al. Validation of HIV-infected cohort identification using automated clinical data in the Department of Veterans Affairs. HIV Medicine. 2019;20:567-570.
11. Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4:2.
12. Thrift AP, Kramer JR, Hartman CM, et al. Risk and predictors of esophageal and stomach cancers in HIV-infected veterans: a matched cohort study. J Acquir Immune Defic Syndr. 2019;81:e65-e72.
13. Robinson M, Sloan P, Shaw R. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol. 2010;46:492-496.
14. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk and survival for oropharynx and HPV-unrelated head and neck squamous cell carcinoma (OPSCC): an extensive review. J Otolaryngol. 2010;39:4.
15. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728-736.
16. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-432.
17. Zullig LL, Sims KJ, McNeil R, et al. Cancer incidence among patients of the U.S. Veterans Affairs Health Care System: 2010 Update. Military Med. 2017;182(7):e1883-e1891.
18. Beachler DC, Abraham AG, Silverberg MJ, et al. Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncol. 2014;50:1169-1176.
19. Engels EA, Madeleine MM. Invited commentary: biological and clinical insights from epidemiologic research into HIV, HPV, and anal cancer. Am J Epidemiol. 2013;178:885-887.
20. D'Souza G, Fakhry C, Sugar EA, et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer. 2007;121:143-150.
21. Beachler DC, Weber KM, Margolick JB, et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomark Prev. 2012;21:122-133.
22. Buggert M, Nguyen S, McLane LM, et al. Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. PLoS Pathog. 2018;14:e1006973.
23. El-Serag HB, Hepworth EJ, Lee P, Sonnenberg A. Gastroesophageal reflux disease is a risk factor for laryngeal and pharyngeal cancer. Am J Gastroenterol. 2001;96:2013-2018.
24. Busch EL, Zevallos JP, Olshan AF. Gastroesophageal reflux disease and odds of head and neck squamous cell carcinoma in North Carolina. Laryngoscope. 2016;126:1091-1096.
25. Anis MM, Razavi MM, Xiao X, Soliman AMS. Association of gastroesophageal reflux disease and laryngeal cancer. World J Otorhinolaryngol Head Neck Surg. 2018;4:278-281.
26. Francis DO, Maynard C, Weymuller EA, Reiber G, Merati AL, Yueh B. Reevaluation of gastroesophageal reflux disease as a risk factor for laryngeal cancer. Laryngoscope. 2011;121:102-105.
27. Park J, McPike V, Kambhampati S, et al. Positivity rates in oropharyngeal and nonoropharyngeal head and neck cancer in the VA. Fed Pract. 2018;35:544-547.
28. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.
29. Heiduschka G, Grah A, Oberndorfer F, et al. Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol. 2015;191:209-216.
30. Haigentz M, Suarez C, Strojan P, et al. Understanding interactions of smoking on prognosis of HPV-associated oropharyngeal cancers. Advances in Therapy. 2018;35:255-260.
31. Sandulache VC, Wilde DC, Sturgis EM, Chiao EY, Sikora AG. A hidden epidemic of "Intermediate Risk" oropharynx cancer. Laryngoscope Investig Otolaryngol. 2019;4:617-623.
32. Kemnade JO, Elhalawani H, Castro P, et al. CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer. Sci Rep. 2020;10:243.
33. D’Souza G, Carey TE, William WN, et al. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014;65:603-610.
34. Whiteside TL. Head and neck carcinoma immunotherapy: facts and hopes. Clin Cancer Res. 2018;24:6-13.
35. Tong CC, Kao J, Sikora AG. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res. 2012;54:266-274.
36. Liu C, Mann D, Sinha UK, Kokot NC. The molecular mechanisms of increased radiosensitivity of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC): an extensive review. J Otolaryngol Head Neck Surg. 2018;47:59.
37. Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med. 2000;160:3252-3257.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Mazul AL, Hartman C, Kramer J, et al. Incidence and survival for oropharynx and non-oropharynx head and neck cancers among veterans living with HIV. Cancer Med. 2020;9:9326–9335. https://doi.org/10.1002/cam4.3539